Thyroid hormones inhibit platelet function and myosin light chain kinase.

Area of Science:

• Biochemistry
• Pharmacology
• Hematology

Background:

• Thyroid hormones exert extranuclear effects beyond their classical roles in metabolism.
• Platelet aggregation and serotonin release are critical processes in hemostasis and thrombosis.
• Myosin light chain kinase (MLCK) plays a key role in platelet activation.

Purpose of the Study:

• To investigate the extranuclear effects of thyroid hormones on human platelet function.
• To determine the specific molecular targets of thyroid hormones in platelets.
• To explore the potential of thyroxine as a pharmacological tool and purification ligand for MLCK.

Main Methods:

• Human platelet aggregation assays using collagen and phorbol ester.
• Measurement of [14C] serotonin release and protein phosphorylation.
• Enzyme inhibition assays with purified human platelet MLCK, protein kinase C, and cAMP-dependent protein kinase.
• Characterization of L-thyroxine's interaction with MLCK using calmodulin competition and affinity chromatography.

Main Results:

• DL-thyroxine and DL-triiodothyronine inhibited collagen-induced platelet aggregation and [14C] serotonin release in a dose-dependent manner.
• Thyroid hormones selectively inhibited MLCK activity, acting as competitive inhibitors towards calmodulin.
• L-thyroxine-affinity chromatography enabled efficient purification of human platelet MLCK.

Conclusions:

• Thyroid hormones, particularly thyroxine, exert direct inhibitory effects on human platelet aggregation and serotonin release.
• Thyroxine's primary mechanism involves the inhibition of myosin light chain kinase activity.
• Thyroxine serves as a valuable pharmacological tool for studying MLCK-mediated platelet reactions and as an effective ligand for MLCK purification.